Company Profile · NASDAQ: NIVF
NewGenIvf Group Limited: What the NIVF Business Actually Is
Before you weigh an NIVF stock price prediction, it helps to know what NewGenIvf Group Limited owns, sells and earns. Here is the full company profile: clinics, treatment services, business divisions, leadership, financials and Nasdaq listing history.
- Ticker
- NIVF (Nasdaq)
- Sector
- Healthcare
- Industry
- Medical care facilities
- Employees
- 87
- Headquarters
- Bangkok, Thailand
- IPO
- March 18, 2022
- Revenue (TTM)
- $4.73M
- Projected Class A shares
- ~8.92M post-split
Who is NewGenIvf Group Limited?
NewGenIvf Group Limited is an investment holding company whose core operating business is assisted reproductive services (ARS) across the Asia-Pacific region. The group describes its mission as helping couples and individuals build families regardless of fertility challenges, and it delivers that mainly through two service lines: in-vitro fertilisation (IVF) treatment, including egg donation, and surrogacy with ancillary caring services. Its clinics are located in Thailand, Cambodia, Hong Kong and Kyrgyzstan.
The company is registered and listed in the United States but operated from Bangkok, Thailand. It is led by Chairman and Chief Executive Officer Siu Wing Fung, with Fai Chung Ho serving as Chief Financial Officer. Group headcount is roughly 87 full-time employees.
Services
The fertility treatment menu behind NIVF revenue
IVF and advanced reproduction
In-vitro fertilisation, ICSI (intracytoplasmic sperm injection), embryo culture, embryo freezing, chromosome screening and hysteroscopy — the clinical core of the ARS business.
Diagnostics and screening
Hormonal blood tests, infectious-disease tests, chromosome screening, sperm analysis, sorting, washing and freezing, plus egg freezing for elective fertility preservation.
Surrogacy and ancillary care
Surrogacy programmes with the caring services that surround them, the higher-ticket end of the group's offering.
Value-added patient services
Nutrition guidance, psychological counselling, acupuncture and translation and interpreter support — the layer that makes a clinic workable for international medical-tourism patients.
Structure
Beyond fertility: NewGenIvf's other divisions
NewGenIvf has positioned itself as a diversified, multi-jurisdictional platform rather than a single-clinic operator. Alongside reproductive health, the group has described divisions spanning real-estate development in the Ras Al Khaimah emirate of the United Arab Emirates, and digital-asset and decentralised-finance solutions. It has also executed a share purchase agreement for an initial equity interest in K25.ai, an AI-powered prediction-market venture, together with an exclusive Asia-Pacific agency agreement covering the same business.
This diversified structure gives NIVF several lines of business that could each produce a catalyst and broaden the company's long-term growth opportunity beyond its core fertility platform.
Financials
NewGenIvf Group Limited at a glance
The site's October 1 historical snapshot reported trailing revenue of roughly $4.73M and net income of about $9.88M. The October 7 filing projected approximately 8.92M Class A shares after the October 12 one-for-four reverse split. A current quote and fully diluted share count must be checked before drawing current valuation conclusions; the split itself does not add business value.
History
Company milestones
- March 18, 2022 — NewGenIvf Group Limited completes its Nasdaq listing under the ticker NIVF.
- NewGenIvf expands its fertility-services footprint across Thailand, Cambodia, Hong Kong and Kyrgyzstan.
- The group adds property and digital-asset divisions to broaden its platform beyond reproductive healthcare.
- NewGenIvf signs for an initial interest in K25.ai together with exclusive Asia-Pacific agency rights.
- October 12, 2026 — a one-for-four reverse split becomes effective, as announced in the October 7 company filing and confirmed by Nasdaq.
Read next
More on NIVF
NIVF stock price prediction
The bull case and the $3–$5 post-split December 2026 scenario.
NIVF stock forecast 2026
Positive price scenarios with the catalyst calendar.
Is NIVF a good investment?
The positive investment case and key growth drivers.
Best penny stocks to buy today
Other low-priced Nasdaq and NYSE names on the watchlist.
Sources & further reading
- Tickeron — NIVF vs VCIG: Two Micro-Caps Navigating AI and Digital Asset Shifts (market commentary)
- NewGen July 30, 2026 announcement — agreed 13% K25.ai stake subject to acquisition completion
- NewGenIvf October 7, 2026 Form 6-K — reverse split and projected Class A share count
- Nasdaq — confirmation of NIVF's October 12, 2026 one-for-four reverse split
- NewGenIVF March 31, 2025 announcement — European Wellness proposed merger terminated
- NewGenIvf Group Limited investor relations — company profile and clinic locations
- Yahoo Finance — NewGenIvf Group Limited (NIVF) quote, price and profile
- CNBC — NIVF quote, key stats, revenue and EBITDA
- StockAnalysis — NewGenIvf Group (NIVF) market cap, shares outstanding, earnings date
- Finviz — NIVF market cap, float, insider ownership, offering news
- TipRanks — 3 Penny Stocks on Investors' Radar, October 1
- MarketBeat — Penny Stocks List, most active shares under $1
- Barchart — Hot Penny Stocks on The Move
Disclaimer: This page is speculative opinion and independent commentary, not financial advice, a recommendation, a solicitation, or an offer to buy or sell any security. Every price target and scenario shown here is a hypothetical illustration, not a forecast or a guarantee. Quoted prices are point-in-time snapshots, not live quotes, and may be stale. Always do your own research and consult a licensed financial advisor before investing.